Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA Approves Lebrikizumab for Atopic Dermatitis
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD) that is not well controlled, despite…
English